Table 2.

Changes over time in hemoglobin and body weight during treatment with placebo or atrasentan

Variable	Time	Placebo		Atrasentan 0.75 mg/d		Atrasentan 1.25 mg/d
	Week	n	Mean±SD or Median	n	Mean±SD or Median	n	Mean±SD or Median
UACR, mg/g	Baseline	50	671	78	878	83	826
	2	48	696	75	573	82	515
	6	48	686	74	636	75	461
	12	48	797	70	521	69	470
	Recovery	45	737	68	1051	71	727
Hemoglobin, g/dl	Baseline	50	12.7±1.8	78	12.9±1.5	83	12.9±1.8
	2	47	12.5±1.9	74	12.0±1.5	80	11.8±1.8
	6	48	12.6±1.9	72	11.9±1.7	73	11.6±1.7
	12	47	12.6±2.1	69	11.8±1.6	68	11.8±1.8
	Recovery	26	12.3±1.9	39	12.4±1.5	47	12.5±1.9
BNP, pg/ml	Baseline	50	31.7	77	33.0	82	33.5
	12	47	35.0	66	33.1	67	37.0
Weight, kg	Baseline	50	84.3±20.2	78	87.1±22.1	83	88.3±18.4
	2	48	83.2±19.6	77	88.0±22.2	82	89.4±18.7
	6	48	83.3±19.6	74	87.3±21.8	75	89.6±19.0
	12	48	82.8±18.6	70	87.3±22.3	69	89.0±19.2
	Recovery	44	83±20	61	85±23	70	88±19

UACR, urinary albumin to creatinine ratio; BNP, B-type natriuretic peptide.